<DOC>
	<DOCNO>NCT02718859</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy combine therapy use irreversible electroporation（IRE）and nature killer ( NK ) cell advanced pancreatic cancer .</brief_summary>
	<brief_title>Combination Irreversible Electroporation NK Immunotherapy Advanced Pancreatic Cancer</brief_title>
	<detailed_description>By enrol patient pancreatic cancer adapt enrolled criterion , study document first time safety short long term efficacy combine therapy use irreversible electroporation（IRE）and nature killer（NK） cell advanced pancreatic cancer . The efficacy evaluate accord relief degree , progress free survival ( PFS ) overall survival ( OS ) . The safety evaluate statistic adverse reaction</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Age:1880 2 . Diagnosis：advanced active pancreatic cancer 3 . The tumour measurable 4 . Eastern Cooperative Oncology Group ( ECOG ) score：0~2；3 relationship tumour 5 . Vital organ function normal : total bilirubin ( TB ) &lt; 68μmol/L aspartate aminotransferase ( AST ) &lt; 90 IU/L Cre &lt; 353μmol/L white blood cell count ( WBC ) &lt; 9×10^9/L , WBC close even great 9×10^9/L，the recommend dose halved platelet count ( PLT ) &gt; 80×10^9/L Red blood cell specific volume ( HCT ) &gt; 0.20 Non severe viral bacterial infection 6 . Non pregnant lactating patient 7 . Non allergic reaction biological product 8 . Informed consent 1 . Patients cardiac pacemaker 2 . Patients severe cardiac pulmonary dysfunction 3 . Patients researcher think fit group , include patient fail compliance assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>advanced pancreatic cancer</keyword>
	<keyword>nature killer cell</keyword>
	<keyword>irreversible electroporation</keyword>
</DOC>